A small country perspective on the future prospects of EU Health Policy



European Public Health 20 years after the Maastricht Treaty:

Turning past experiences into visions

Maastricht, 22 - 23 May 2013

Dr. Natasha Azzopardi Muscat Chief Medical Officer Malta



Outline

Α

- The small vs. big Member States debate
- Challenges faced by small MS the health system vulnerability model

В

- The EU's role in health
- Taking stock of pre- and post- EU accession influence on Malta's healthcare system

C

 The EU Patients' Rights Directive: challenges for a small country?


D


What's next? A vision for the future

A. The small vs. big Member States debate

- An enlarging and expanding EU
- After the historic 2004 (CEE/SE) enlargement: new and smaller MS
- From the big 6 founding fathers nearly 28 members
- 12 MS' population: >50 million 10 million
- 7 MS' population: 10 million 6 million
- 8 MS' population: 5 million < 1 million

A. The small vs. big Member States debate





What is a small country?

Germany

81. 8 million

Netherlands

16. 7 million

Finland

5. 4 million

Ireland

4.6 million


Luxembourg

0.5 million

Malta

0.4 million

Challenges faced by small MS – the health system vulnerability model




Small size: small population

Inability to achieve sustainable volumes of activity

Limited contributor pool in sharing pop. resources (gene types, organs)

Difficulties with rare diseases: not enough patients to justify availability of treatment



Lack of infrastructure investment

Quality issues associated with low throughput


Deskilling

Inability to offer all services esp. highly specialised care

Small size: small economy

Administrative burden of regulation

High or inefficient unit costs of production



Lack of competition between providers


Lack of interest by industry to place medical goods on the market

High prices for medicines and medical supplies due to small volumes of consumption

Insularity

Difficulty segregating roles in the health system

Lack of peer review available at national level



Quality issues may remain unnoticed


Access to innovation may be delayed

Lack of mobility - stagnation

Remoteness




Difficult access to specialist centres in life threatening situations



Critical timing issues hinder rapid intervention in organ retrieval and implantation

Have the EU's health policies recognised the vulnerabilities of small MS'?

1992: the Maastricht Treaty gave the EU a legal public health mandate



Article 152 EC (168 TFEU)

"A high level of human health protection shall be ensured in the definition and implementation of all Union policies and activities"

 Yet, health and healthcare systems remain a Member State competence

The EU has a complementary and supporting role but shapes the conditions for:

- Contracting of employees
- Health workforce mobility
- Purchase of goods and supplies
- Financing of health systems
- Delivery of services

- Taking stock of pre- and post- EU accession influence on Malta's healthcare system:
- Pre-accession crystal ball gazing (May 2003)
 identified 4 major areas of potential influence:
- **→** Medicines
- > Healthcare workforce
- Movement of patients
- ➤ Service delivery




Medicines









The industry grew & became an important sector

- Product list initially diminished& gradually grew again
- New medicines introduced more rapidly

Healthcare workforce



- Development of structured formal specialist training
- •Development of specific vocational training for General Practitioners
- Possible brain drain



•Sustained development of post graduate training: partnerships with EU countries

 Initial medical graduate brain drain counteracted by timely local policy response

Movement of patients



 Uncertain of the impact on patient mobility as high-level reflection process on crossborder health services was underway




- Minimal impact due to the National Highly Specialised Referrals Programme
- Positive impact with some access to transplant waiting lists
- Awaiting outcome of Patients' Rights Directive

Service delivery



•Feared harmonisation pressures would have negative effects on the health system

 Unaware that EU cohesion funds could be used for health



Introduction of cancer screening programmes

Successfully obtained
 Structural Funds to build and equip an oncology centre

infrastructure

What is the stance of the European Commission towards small MS?



- Its positions are marginally closer to those of small MS
- Viewed as a natural ally of small MS
- Better transposition compliance by small MS (especially before and around 2004)
- Smaller MS tend to have a more positive approach to networks, exchange of best practices and EU processes

A special mention of small MS

- Cyprus clause (Article 126a)
 - Abridged form of registration for medicines
 - Reduced administrative burden on industry and regulator
- Ex-ante impact assessment of the Patients' Rights
 Directive (2008): small MS may have higher rates of
 cross-border healthcare with a higher financial
 impact.
- In fact, according to Eurobarometer: Luxembourg spends the highest % of its healthcare budget on Xborder healthcare

Do proposed EU policies exacerbate the weak areas of smaller MS or support them in building economic and health system resilience?

C. The EU Patients' Rights Directive: challenges for a small country?

- Information provision National Contact Point
- Health Technology Assessment (HTA)
- E-prescriptions
- Patient/health professional mobility (high outflow?)
- European Reference Networks (complementing gaps at national level?)
- Burden of reimbursement of treatment costs
- Widening inequalities between and within MS?

C. The EU Patients' Rights Directive: challenges for a small country?

Do-ability and fairness of EU health policy for small MS?

- organisational, financial & administration pressures
- reporting requirements

human resources required



D. What's next? A vision for the future





In order to achieve a highlevel of health, EU health policies need to recognise & tackle the inherent health system vulnerabilities faced by small MS...

Future EU health policy needs to...

Develop a new socioeconomic paradigm

- Acknowledges the growing drift between expectations and realities
- Find an equilibrium between raising citizen expectations and the current crisis/supply constraint scenarios
- Ensure that it is not exacerbate growing inequalities further

Reduce administrative burdens

- Minimize and simplify reporting obligations (SF projects) in line with the EU's better regulation agenda
- Avoid new bureaucracies and competent authorities

Future EU health policy also needs to...

- stimulate engagement with all powerful stakeholders
- work towards achieving more policy coherence and inter-sectoral alignment of health policy
- be part of a health policyfriendly European semester process

- ensure access to medicines at affordable prices
- Establish better capacity building programmes amongst public health leaders and practitioners
- encourage pooling of resources and expertise across MS for quality standards oversight

D. What's next? A vision for the future

Whether big or small, let's endorse "Unity in Diversity" & strive for a futuristic EU health policy which:

Recognises disparity
Understands diversity

AND

Works to reduce disparity whilst respecting diversity!



A brave new Europe

We must overcome our fears and insecurities and be ready to give up a little of our pride and latitude and duly recognise that, with the changing environment we are more likely to be successful if we pool our expertise, clout and resources together to develop fresh perspective on health policy that is meaningful to the needs and aspirations of Europe's citizens!



